Lunit subsidiary Volpara Health‘s volumetric breast density assessment has been integrated into the newly released version of the BOADICEA (also known as CanRisk) breast cancer risk model.
Studies have shown the use of Volpara density in BOADICEA to improve model accuracy compared with using BI-RADS density categories, the company said.
Volpara also reported that it has inked an agreement with Optellum, an AI lung cancer diagnosis developer. The partnership will allow Volpara customers to use Optellum’s Virtual Nodule Clinic software, which assesses the probability that a lung nodule is cancerous.
Finally, Volpara highlighted changes to its executive team, noting that Craig Hadfield, its chief customer and financial officer, will become CEO on April 1, succeeding Teri Thomas. Hadfield has been instrumental in Volpara’s financial growth, SaaS transition, and strategic acquisitions, it said.